Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective
Author(s): Timko Robert J, Crooker Philip EM
Issue: Mar/Apr 2014 - Volume 18, Number 2
View All Articles in Issue
Page(s): 101-111
Download in electronic PDF format for $75
Abstract: At one time, nearly all prescriptions were compounded preparations. There is an ongoing demand for compounded prescription medications because manufacturers cannot fulfill the needs of all individual patients. Compounding pharmacies are a long standing yet less frequently discussed element in the complex matrix of prescription drug manufacturing, distribution, and patient use. The drug shortage situation for many necessary and life-saving drug products is a complicating factor that has led to the numerous quality issues that currently plague large-scale compounding pharmacies. The states are the primary regulator of pharmacies, including community drug stores, large chains, and specialty pharmacies. Pharmacies making and distributing drugs in a way that is outside the bounds of traditional pharmacy compounding are of great concern to the U.S. Food and Drug Administration. The U.S. Congress has recently passed the Drug Quality and Security Act. This legislation establishes a clear boundary between traditional compounders and compounding manufacturers. It clarifies a national, uniform set of rules for compounding manufacturers while preserving the states’ primary role in traditional pharmacy regulation. It clarifies the U.S. Food and Drug Administration’s authority over the compounding of human drugs while requiring the Agency to engage and coordinate with states to ensure the safety of compounded drugs.
Related Keywords:
Robert J. Timko, RPh, PhD, Philip E.M. Crooker, compounding history, traditional compounding, U.S. Drug Quality and Security Act, drug safety, pharmacy regulation, pharmaceutical manufacturing, state boards of pharmacy, drug contamination, outsourcing facilities, good manufacturing practices, professional pharmacy compounding associations
Related Categories:
HISTORY, LEGAL, QUALITY CONTROL, PATIENT EDUCATION, UNITED STATES PHARMACOPEIA CONVENTIONS, PROFESSIONAL ISSUES
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective
Timko Robert J, Crooker Philip EM
|
Mar/Apr 2014
Pg. 101-111
|
Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R, Newton Gail D
|
May/Jun 2004
Pg. 181-185
|
Standing Together Fixing the Drug Quality and Security Act
Miller David G
|
Mar/Apr 2015
Pg. 104-106
|
PreScription: Drug Quality and Security Act Implementation Subcommittee Hearing
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 92
|
Applying Quality of Design Concepts to Pharmacy Compounding
Timko Robert J
|
Nov/Dec 2015
Pg. 453-463
|
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Allen Loyd V Jr
|
Jul/Aug 2016
Pg. 351
View Sample |
Documentation: Records and Reports
Akers Michael J
|
Sep/Oct 2017
Pg. 373-380
|
The Role of Compounding in Closing Therapeutic Gaps--Abstracts from FIP 2013
Lutz Eugene, Pauletti Giovanni, Carvalho Maria, Davidson Gigi, Ashworth Lisa, Subramaniam Vaiyapuri, Llambí Francesc
|
Jan/Feb 2014
Pg. 6-12
|
Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Allen W Chris, Greeson Nicole MH, Mixon William
|
Nov/Dec 2020
Pg. 451-458
|
Pharmaceutical Compounding: The Oldest, Most Symbolic, and Still Vital Part of Pharmacy
Kochanowska-Karamyan Anna J
|
Sep/Oct 2016
Pg. 367-374
|
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Allen Loyd V Jr
|
Sep/Oct 2015
Pg. 389-390
|
Incorporating Quality Assurance in Pharmaceutical Compounding-related Courses in the PharmD Curricula
Hossain Mohammad Faisal, Levesque Dan, Frye John, Rashid Mamoon
|
Jul/Aug 2020
Pg. 322-326
|
U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013
Miller David G
|
Jan/Feb 2014
Pg. 35-36
|
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Allen Loyd V Jr
|
Sep/Oct 2017
Pg. 356
|
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Allen Loyd V Jr
|
Nov/Dec 2015
Pg. 487-488
|
Current Topical Treatments in Wound Healing - Part 1
Helmke Christopher D
|
Jul/Aug 2004
Pg. 269-274
|
Regulatory and Operational Issues of Founding a Compounding Pharmacy
Smith Lisa K
|
Nov/Dec 2002
Pg. 434-437
|
Quality Assurance and Quality Control: Being Prepared for U.S. Food and Drug Administration Inspections and Staying in Compliance with United States Pharmacopeia Chapter <797>: Part 1
Martin Matt
|
Sep/Oct 2018
Pg. 401-404
|
Legislative/Regulatory Update: From the International Academy of Compounding Pharmacists: Appropriations
McCrory Gary
|
Mar/Apr 2016
Pg. 95-96
|
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Cabaleiro Joe
|
Sep/Oct 2021
Pg. 358-362
|
Return to Top |